Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)

被引：0
|
作者：
Chan, A.
Yamamoto, D.
Bell, R.
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Kansai Med Univ, Hirakata, Osaka, Japan
[3] Andrew Love Canc Ctr, Geelong, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1139
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [2] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] PertuzumabIn the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Gillian M. Keating
    [J]. Drugs, 2012, 72 : 353 - 360
  • [4] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    [J]. DRUGS, 2012, 72 (03) : 353 - 360
  • [5] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [6] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [7] First-line treatment of HER2-positive metastatic breast cancer (HER2+MBC) with trastuzumab, doectaxel and vinorelbine: results of a Minnie Pearl Cancer Research Network trial
    Yardley, Denise
    Greco, Anthony
    Porter, Lester L., III
    Burris, Howard A., III
    Phelps, Cindy
    Webb, Charles
    Schlabach, Larry
    Fichtel, Lisa
    Hainsworth, John D.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 39 - 39
  • [8] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [9] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    [J]. Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [10] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
12345